Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDiaz-Arocutipa, Carlos
dc.contributor.authorBenites-Meza, Jerry K.
dc.contributor.authorChambergo-Michilot, Diego
dc.contributor.authorBarboza, Joshuan J.
dc.contributor.authorPasupuleti, Vinay
dc.contributor.authorBueno, Héctor
dc.contributor.authorSambola Ayala, Antonia
dc.date.accessioned2022-04-06T07:08:28Z
dc.date.available2022-04-06T07:08:28Z
dc.date.issued2021-06
dc.identifier.citationDiaz-Arocutipa C, Benites-Meza JK, Chambergo-Michilot D, Barboza JJ, Pasupuleti V, Bueno H, et al. Efficacy and Safety of Colchicine in Post–acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med. 2021 Jun;8:676771.
dc.identifier.issn2297-055X
dc.identifier.urihttp://hdl.handle.net/11351/7309
dc.descriptionColchicine; Inflammation; Myocardial infarction
dc.description.abstractBackground: Inflammation plays a key role in atherosclerotic plaque destabilization and adverse cardiac remodeling. Recent evidence has shown a promising role of colchicine in patients with coronary artery disease. We evaluated the efficacy and safety of colchicine in post–acute myocardial infarction (MI) patients. Methods: We searched five electronic databases from inception to January 18, 2021, for randomized controlled trials (RCTs) evaluating colchicine in post–acute MI patients. Primary outcomes were cardiovascular mortality and recurrent MI. Secondary outcomes were all-cause mortality, stroke, urgent coronary revascularization, levels of follow-up high-sensitivity C-reactive protein (hs-CRP), and drug-related adverse events. All meta-analyses used inverse-variance random-effects models. Results: Six RCTs involving 6,005 patients were included. Colchicine did not significantly reduce cardiovascular mortality [risk ratio (RR), 0.91; 95% confidence interval (95% CI), 0.52–1.61; p = 0.64], recurrent MI (RR, 0.87; 95% CI, 0.62–1.22; p = 0.28), all-cause mortality (RR, 1.06; 95% CI, 0.61–1.85; p = 0.78), stroke (RR, 0.28; 95% CI, 0.07–1.09; p = 0.05), urgent coronary revascularization (RR, 0.46; 95% CI, 0.02–8.89; p = 0.19), or decreased levels of follow-up hs-CRP (mean difference, −1.95 mg/L; 95% CI, −12.88 to 8.98; p = 0.61) compared to the control group. There was no increase in any adverse events (RR, 0.97; 95% CI, 0.89–1.07; p = 0.34) or gastrointestinal adverse events (RR, 2.49; 95% CI, 0.48–12.99; p = 0.20). Subgroup analyses by colchicine dose (0.5 vs. 1 mg/day), time of follow-up (<1 vs. ≥1 year), and treatment duration (≤30 vs. >30 days) showed no changes in the overall findings. Conclusion: In post–acute MI patients, colchicine does not reduce cardiovascular or all-cause mortality, recurrent MI, or other cardiovascular outcomes. Also, colchicine did not increase drug-related adverse events.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Cardiovascular Medicine;8
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectInfart de miocardi - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshMyocardial Infarction
dc.subject.mesh/drug therapy
dc.subject.meshTreatment Outcome
dc.titleEfficacy and Safety of Colchicine in Post–acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fcvm.2021.676771
dc.subject.decsinfarto de miocardio
dc.subject.decs/farmacoterapia
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.3389/fcvm.2021.676771
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Diaz-Arocutipa C] Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. Programa de Atención Domiciliaria – EsSalud, Lima, Peru. [Benites-Meza JK] Tau Relaped Group, Trujillo, Peru. Facultad de Medicina, Universidad Nacional de Trujillo, Trujillo, Peru. [Chambergo-Michilot D] Tau Relaped Group, Trujillo, Peru. Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, Peru. [Barboza JJ] Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. Tau Relaped Group, Trujillo, Peru. [Pasupuleti V] MedErgy HealthGroup, Inc., Yardley, PA, United States. [Bueno H] Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. Cardiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. [Sambola A] Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34169101
dc.identifier.wos000664073300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record